# Assertio Holdings Inc. (ASRT)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $150M  
**Price:** $23.48 (+0.02%)

> Assertio Holdings Inc. is a leading commercial pharmaceutical company that brings differentiated branded prescription products to patients across key therapeutic areas. It maintains a robust portfolio focused on neurology, inflammation, pain management, oncology, and hospital products, including medications such as INDOCIN for treating rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, gouty arthritis, and acute painful shoulder; Sympazan, a benzodiazepine for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome; Otrexup, SPRIX, CAMBIA, and Zipsor; as well as Rolvedon in oncology following strategic business development. The company specializes in acquiring, licensing, and optimizing commercial-stage assets through an acquisition-driven model, emphasizing targeted marketing and lifecycle management to serve patients primarily in the United States. Founded in 1995 and headquartered in Lake Forest, Illinois, Assertio Holdings Inc. plays a vital role in the specialty pharmaceuticals sector by providing established, high-margin products in neuroscience, immunology, and oncology.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $119M | — | -$22M | -$30M | — |
| 2024 | $125M | — | -$24M | -$22M | — |
| 2023 | $152M | — | -$244M | -$332M | — |
| 2022 | $156M | — | $39M | $110M | — |
| 2021 | $111M | $95M | $9M | -$1M | — |
| 2020 | $106M | $86M | -$82M | -$28M | — |
| 2019 | $230M | $220M | -$194M | -$217M | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $267M | $173M | $94M | $10M | $39M |
| 2024 | $285M | $164M | $121M | $51M | $39M |
| 2023 | $286M | $148M | $138M | $73M | $39M |
| 2022 | $414M | $188M | $226M | $65M | $67M |
| 2021 | $327M | $224M | $102M | $37M | $73M |
| 2020 | $303M | $248M | $56M | $21M | $84M |
| 2019 | $527M | $469M | $58M | $42M | $351M |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$28M | — | — |
| 2024 | $26M | — | $26M |
| 2023 | $50M | $628,000 | $49M |
| 2022 | $79M | $274,000 | $78M |
| 2021 | $6M | $53,000 | $5M |
| 2020 | -$66M | $10,000 | -$66M |
| 2019 | $90M | $1M | $89M |

Source: [CompaniesByCap](https://companiesbycap.com/company/ASRT)